Leveraging Early Mechanistic & Translational Data to Establish Safer Next-Generation T-Cell Engager Therapies for Autoimmune Disease
- Presenting a comprehensive suite of in vitro and in vivo translational datasets characterizing the mechanism of action, immune-cell engagement dynamics, and functional activity of Synolo Therapeutics’ novel T-cell engager platform across autoimmune-relevant models
- Evaluating cytokine release, immune-cell activation profiles, and safety-associated biomarkers through advanced in vitro assays and preclinical studies to demonstrate how differentiated engager design strategies can achieve improved safety thresholds while retaining therapeutic potency
- Integrating early mechanistic insights with translational biomarker analyses to establish predictive frameworks that support candidate selection, de-risk clinical development, and accelerate the translation of safer T-cell engager therapies into human studies